key: cord-0879984-886t5s6x authors: Durmus, Oyku; Akdogan, Neslihan; Karadag, Omer; Gokoz, Ozay title: Erythroderma related with the first dose of Pfizer‐BioNTech BNT16B2b2 COVID‐19 mRNA vaccine in a patient with psoriasis date: 2022-02-14 journal: Dermatol Ther DOI: 10.1111/dth.15363 sha: 00156a1dcfbbef2198d7a4930f97fb3550a7ae71 doc_id: 879984 cord_uid: 886t5s6x nan A provisional diagnosis of erythrodermic psoriasis was made (PASI: 48.6, Body surface area: 95%, Figure 1A -D). The patient had itch, pain, malaise, and fatigue. Physical examination did not reveal tachycardia, hypothermia, hyperthermia, peripheral lymphadenopathy, and facial, pedal or pretibial edema. Laboratory investigation revealed neutrophilia, leukocytosis, and elevated serum C-reactive protein levels, while serum albumin and total protein levels were normal. Four-mm punch biopsy taken from the right lateral thigh revealed hyperkeratosis, parakeratosis, and small focus of neutrophil deposits in the stratum corneum. Additionally, focal spongiosis, regular acanthosis hypogranulosis, thinning of the suprapapillary plates, and lymphohistiocytic inflammatory infiltrate in the dermis were seen indicating psoriasis ( Figure 1E ). Oral prednisone was initiated with a dose of 50 mg daily, followed by 10 mg weekly dose reduction. While the prednisone dose was tapered, secukinumab treatment was switched to ixekizumab. Ixekizumab was administered according to the rec- Although psoriasis flare-up after COVID-19 vaccination was considered to be rare, patients with plaque, palmoplantar, guttate and pustular type psoriasis were reported to be flare-up after COVID-19 vaccine which were summarized in Table 1 . [1] [2] [3] [4] [5] [6] [7] [8] In most studies, duration between the vaccination and the flare of psoriasis is between 1 and 14 days, but there are also studies reporting the duration between the vaccination and the flare of psoriasis longer than 14 days, as in our case. 6, 7 Biologic agents may strongly reduce but The authors have no conflict of interest to declare. Written informed consent for publication of medical images was taken from the patient. Data sharing not applicable to this article as no new data generated, or the article describes entirely theoretical research. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine New onset of remitting seronegative symmetrical synovitis with pitting Oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: a report of two cases Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single Centre Fabbrocini G. reply to "psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single Centre COVID-19 vaccination and patients with psoriasis under biologics: reallife evidence on safety and effectiveness from Italian vaccinated healthcare workers Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients